公开(公告)号：US12077558B2

公开(公告)日：2024-09-03

申请号：US18167772

申请日：2023-02-10

申请人： Bristol-Myers Squibb Company ,  The Scripps Research Institute

发明人： Michael Anthony Schmidt ,  Bin Zheng ,  Kyle Knouse ,  Justine deGruyter ,  Martin D. Eastgate ,  Phil Baran ,  William R. Ewing ,  Richard E. Olson ,  Ivar M. McDonald

IPC分类号： C07H21/00 ,  C07H19/11 ,  C07H19/213

CPC分类号： C07H21/00

摘要： The present invention relates to novel phosphorous (V) (P(V)) reagents, methods for preparing thereof, and methods for preparing organophosphorous (V) compounds by using the novel reagents.

公开(公告)号：US11613554B2

公开(公告)日：2023-03-28

申请号：US16382692

申请日：2019-04-12

申请人： Bristol-Myers Squibb Company ,  The Scripps Research Institute

发明人： Michael Anthony Schmidt ,  Bin Zheng ,  Kyle Knouse ,  Justine deGruyter ,  Martin D. Eastgate ,  Phil Baran ,  William R. Ewing ,  Richard E. Olson ,  Ivar M. McDonald

IPC分类号： C07H21/00

摘要： The present invention relates to novel phosphorous (V) (P(V)) reagents, methods for preparing thereof, and methods for preparing organophosphorous (V) compounds by using the novel reagents.

公开(公告)号：US12065505B2

公开(公告)日：2024-08-20

申请号：US17570649

申请日：2022-01-07

申请人： Bristol-Myers Squibb Company ,  Janssen Pharmaceuticals, Inc.

发明人： Joseph M. Luettgen ,  Lumelle Schneeweis ,  Ginger Chao Rakestraw ,  Christina Terragni ,  Andrew Karl Dilger ,  Jason Robert Pinckney ,  Steven Sheriff ,  Kevin Kish ,  Yongmi An ,  William R. Ewing ,  Stanley Richard Krystek, Jr. ,  Aaron Paul Yamniuk

IPC分类号： C07K16/36 ,  A61K39/00 ,  A61P7/04 ,  C07K16/44 ,  G01N33/86 ,  G01N33/94

CPC分类号： C07K16/36 ,  A61P7/04 ,  C07K16/44 ,  G01N33/86 ,  G01N33/94 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/92

摘要： The present invention provides novel antigen binding peptides, such as an antibody or antibody fragment, that specifically bind to selective FXIa inhibitors and/or dual inhibitors of FXIa, and plasma kallikrein. The present invention further relates to methods of reducing the antithrombotic effect of FXIa inhibitors by administering to a subject a pharmaceutically effective dose of the antigen binding peptides provided herein. In addition, the present invention provides detection reagents and methods for detecting the level of the inhibitors of FXIa in a biological sample.

公开(公告)号：US11192891B2

公开(公告)日：2021-12-07

申请号：US16760682

申请日：2018-11-01

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Yeheng Zhu ,  Sunita V. Dewnani ,  William R. Ewing

IPC分类号： C07D471/10 ,  A61K31/438 ,  A61K9/00 ,  C07D487/10

摘要： The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

公开(公告)号：US20210188848A1

公开(公告)日：2021-06-24

申请号：US16760682

申请日：2018-11-01

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Yeheng Zhu ,  Sunita V. Dewnani ,  William R. Ewing

IPC分类号： C07D471/10 ,  C07D487/10 ,  A61K9/00

摘要： The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

公开(公告)号：US10676477B2

公开(公告)日：2020-06-09

申请号：US15747867

申请日：2016-07-28

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Yeheng Zhu ,  Andrew K. Dilger ,  William R. Ewing ,  Michael J. Orwat ,  Donald J. P. Pinto

IPC分类号： C07D487/04 ,  C07D403/14 ,  C07D401/14 ,  C07D403/12 ,  A61P7/02

摘要： The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

公开(公告)号：US20190382378A1

公开(公告)日：2019-12-19

申请号：US16454848

申请日：2019-06-27

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： James R. Corte ,  William R. Ewing ,  Donald J.P. Pinto ,  Leon M. Smith, II

IPC分类号： C07D403/10 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D401/10 ,  C07D237/14 ,  C07D403/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08 ,  C07D471/10 ,  C07D487/04 ,  A61P7/02 ,  C07D211/86 ,  C07D409/14 ,  C07D498/04

摘要： The present invention provides compounds of Formula (I): (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

公开(公告)号：US10081623B2

公开(公告)日：2018-09-25

申请号：US15508122

申请日：2015-09-03

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Jun Shi ,  William R. Ewing ,  Laura Nielsen ,  Zilun Hu ,  Mimi L. Quan

IPC分类号： C07D401/06 ,  C07D403/06 ,  C07D403/12 ,  C07D409/12 ,  C07D401/12

CPC分类号： C07D409/12 ,  C07D401/06 ,  C07D401/12 ,  C07D403/06 ,  C07D403/12

摘要： The present invention provides compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

公开(公告)号：US20170283403A1

公开(公告)日：2017-10-05

申请号：US15508122

申请日：2015-09-03

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Jun Shi ,  William R. Ewing ,  Laura Nielsen ,  Zilun HU ,  Mimi L. Quan

IPC分类号： C07D409/12 ,  C07D401/06 ,  C07D403/06 ,  C07D403/12 ,  C07D401/12

CPC分类号： C07D409/12 ,  C07D401/06 ,  C07D401/12 ,  C07D403/06 ,  C07D403/12

摘要： The present invention provides compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

公开(公告)号：US09611274B2

公开(公告)日：2017-04-04

申请号：US14942013

申请日：2015-11-16

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Donald J. P. Pinto ,  James R. Corte ,  Paul J. Gilligan ,  Tianan Fang ,  Leon M. Smith, II ,  Yufeng Wang ,  Wu Yang ,  William R. Ewing

IPC分类号： C07D487/08 ,  C07D498/06 ,  C07D471/06 ,  C07D487/06

CPC分类号： C07D519/00 ,  C07D471/06 ,  C07D471/08 ,  C07D487/06 ,  C07D487/08 ,  C07D498/06 ,  C07D498/08

摘要： The present invention provides compounds of Formula (Ia): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.